Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17–48 (2023).ArticleÂ
Google ScholarÂ
Gadducci, A. et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J. Ovarian Res. 12 (1), 9 (2019).ArticleÂ
PubMed CentralÂ
Google ScholarÂ
Munoz-Galvan, S. et al. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Mol. Cancer. 19 (1), 7 (2020).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Asare-Werehene, M. et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 39 (7), 1600–1616 (2020).ArticleÂ
CASÂ
Google ScholarÂ
Schwartz, A. L. & Ciechanover, A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 49, 73–96 (2009).ArticleÂ
CASÂ
Google ScholarÂ
Devoy, A., Soane, T., Welchman, R. & Mayer, R. J. The ubiquitin-proteasome system and cancer. Essays Biochem. 41, 187–203 (2005).ArticleÂ
CASÂ
Google ScholarÂ
Hickey, C. M., Xie, Y. & Hochstrasser, M. DNA binding by the MATalpha2 transcription factor controls its access to alternative ubiquitin-modification pathways. Mol. Biol. Cell. 29 (5), 542–556 (2018).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell. 92 (3), 367–380 (1998).ArticleÂ
CASÂ
Google ScholarÂ
Nath, D. & Shadan, S. The ubiquitin system. Nature. 458 (7237), 421 (2009).ArticleÂ
ADSÂ
CASÂ
Google ScholarÂ
Rao, Z. & Ding, Y. Ubiquitin pathway and ovarian cancer. Curr. Oncol. 19 (6), 324–328 (2012).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Song, M. et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat. Commun. 11 (1), 6298 (2020).ArticleÂ
ADSÂ
MathSciNetÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 39 (7), 928–944e926 (2021).ArticleÂ
CASÂ
Google ScholarÂ
Jiang, Y., Wang, C. & Zhou, S. Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochim. Biophys. Acta Rev. Cancer. 1873 (2), 188361 (2020).ArticleÂ
CASÂ
Google ScholarÂ
Kawamura, K., Komohara, Y., Takaishi, K., Katabuchi, H. & Takeya, M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 59 (5), 300–305 (2009).ArticleÂ
Google ScholarÂ
Xu, J. et al. Single-cell RNA sequencing reveals the tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin. Cancer Res. 28 (16), 3590–3602 (2022).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Zhang, T. et al. Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer. J. Int. Med. Res. 49 (12), 3000605211066245 (2021).ArticleÂ
ADSÂ
CASÂ
Google ScholarÂ
Wahner Hendrickson, A. E. et al. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol. Oncol. 137 (1), 77–85 (2015).ArticleÂ
Google ScholarÂ
Bodelon, C. et al. Molecular classification of epithelial ovarian Cancer based on methylation profiling: evidence for Survival Heterogeneity. Clin. Cancer Res. 25 (19), 5937–5946 (2019).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (1), 27–30 (2000).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28 (11), 1947–1951 (2019).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (D1), D587–d592 (2023).ArticleÂ
CASÂ
Google ScholarÂ
Zwickl, P., Voges, D. & Baumeister, W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos. Trans. R Soc. Lond. B Biol. Sci. 354 (1389), 1501–1511 (1999).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Wu, Y. et al. Development of an Individualized Ubiquitin Prognostic signature for Clear Cell Renal Cell Carcinoma. Front. Cell. Dev. Biol. 9, 684643 (2021).ArticleÂ
PubMed CentralÂ
Google ScholarÂ
Chen, X. et al. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer. J. Gene Med. 26(1):e3584. (2023).Ni, W. et al. Identification and validation of Ubiquitin-Specific proteases as a Novel Prognostic signature for Hepatocellular Carcinoma. Front. Oncol. 11, 629327 (2021).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Song, G. et al. Identification of a Ubiquitin related genes signature for Predicting prognosis of prostate Cancer. Front. Genet. 12, 778503 (2021).ArticleÂ
CASÂ
Google ScholarÂ
Haase, M. & Fitze, G. HSP90AB1: helping the good and the bad. Gene. 575 (2 Pt 1), 171–186 (2016).ArticleÂ
CASÂ
Google ScholarÂ
Nikishin, D. A. et al. Selection of stable expressed reference genes in native and vitrified/thawed human ovarian tissue for analysis by qRT-PCR and Western blot. J. Assist. Reprod. Genet. 35 (10), 1851–1860 (2018).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Hussain, S. et al. F-box only protein 9 and its role in cancer. Mol. Biol. Rep. 49 (2), 1537–1544 (2022).ArticleÂ
CASÂ
Google ScholarÂ
Foulkes, W. D., Ragoussis, J., Stamp, G. W., Allan, G. J. & Trowsdale, J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br. J. Cancer. 67 (3), 551–559 (1993).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Xu, Q. et al. Sigma-1 receptor (σ1R) is downregulated in hepatic malignant tumors and regulates HepG2 cell proliferation, migration and apoptosis. Oncol. Rep. 39 (3), 1405–1413 (2018).CASÂ
Google ScholarÂ
Koti, M. et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br. J. Cancer. 112 (7), 1215–1222 (2015).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Au, K. K. et al. STAT1-associated intratumoural T(H)1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J. Pathol. Clin. Res. 2 (4), 259–270 (2016).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Josahkian, J. A. et al. Increased STAT1 expression in high Grade Serous Ovarian Cancer is Associated with a better outcome. Int. J. Gynecol. Cancer. 28 (3), 459–465 (2018).ArticleÂ
Google ScholarÂ
Li, X., Wang, F., Xu, X., Zhang, J. & Xu, G. The dual role of STAT1 in Ovarian Cancer: insight into Molecular mechanisms and Application potentials. Front. Cell. Dev. Biol. 9, 636595 (2021).ArticleÂ
PubMed CentralÂ
Google ScholarÂ
Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21 (4), 687–692 (2015).ArticleÂ
CASÂ
Google ScholarÂ
Meissl, K., Macho-Maschler, S., Müller, M. & Strobl, B. The good and the bad faces of STAT1 in solid tumours. Cytokine. 89, 12–20 (2017).ArticleÂ
CASÂ
Google ScholarÂ
Jin, Y. et al. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway. Int. Immunopharmacol. 70, 1–8 (2019).ArticleÂ
CASÂ
Google ScholarÂ
Osterberg, L. et al. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas. BMC Cancer. 9, 368 (2009).ArticleÂ
PubMed CentralÂ
Google ScholarÂ
Menyhárt, O., Fekete, J. T. & GyÅ‘rffy, B. Gene expression indicates altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer patients resistant to Topotecan. Int. J. Mol. Sci. 20(11), 2750 (2019).Zhang, L. et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer. Mol. Cancer. 18 (1), 144 (2019).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Huang, T. et al. Autophagy and Hallmarks of Cancer. Crit. Rev. Oncog. 23 (5–6), 247–267 (2018).ArticleÂ
PubMed CentralÂ
Google ScholarÂ
Segala, G. et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling. Nat. Commun. 10 (1), 1833 (2019).ArticleÂ
ADSÂ
PubMed CentralÂ
Google ScholarÂ
D’Arca, D. et al. Serum Mass Spectrometry Proteomics and Protein Set Identification in response to FOLFOX-4 in drug-resistant ovarian carcinoma. Cancers (Basel) 15(2), 412 (2023).Lin, Y. R., Yang, W. J. & Yang, G. W. Prognostic and immunological potential of PPM1G in hepatocellular carcinoma. Aging (Albany NY). 13 (9), 12929–12954 (2021).ArticleÂ
CASÂ
Google ScholarÂ
Di, C. et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell. Death Differ. 26 (7), 1181–1194 (2019).ArticleÂ
CASÂ
Google ScholarÂ
Radeva, M. Y., Kugelmann, D., Spindler, V. & Waschke, J. PKA compartmentalization via AKAP220 and AKAP12 contributes to endothelial barrier regulation. PLoS One. 9 (9), e106733 (2014).ArticleÂ
ADSÂ
PubMed CentralÂ
Google ScholarÂ
Liang, Q. et al. Pan-cancer analysis of the prognosis and immunological role of AKAP12: a potential biomarker for resistance to anti-VEGF inhibitors. Front. Genet. 13, 943006 (2022).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Goel, R. K. & Lukong, K. E. Understanding the cellular roles of fyn-related kinase (FRK): implications in cancer biology. Cancer Metastasis Rev. 35 (2), 179–199 (2016).ArticleÂ
CASÂ
Google ScholarÂ
Brauer, P. M. & Tyner, A. L. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell. Cycle. 8 (17), 2728–2732 (2009).ArticleÂ
CASÂ
Google ScholarÂ
Yu, X. Z. et al. TRIM44 facilitates ovarian cancer proliferation, migration, and invasion by inhibiting FRK. Neoplasma. 68 (4), 751–759 (2021).ArticleÂ
CASÂ
Google ScholarÂ
Altemus, M. A. et al. Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes. PLoS One. 14 (9), e0220973 (2019).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Wang, Z., Han, G., Liu, Q., Zhang, W. & Wang, J. Silencing of PYGB suppresses growth and promotes the apoptosis of prostate cancer cells via the NF–κB/Nrf2 signaling pathway. Mol. Med. Rep. 18 (4), 3800–3808 (2018).CASÂ
PubMed CentralÂ
Google ScholarÂ
Shimada, S., Shiomori, K., Tashima, S., Tsuruta, J. & Ogawa, M. Frequent p53 mutation in brain (fetal)-type glycogen phosphorylase positive foci adjacent to human ‘de novo’ colorectal carcinomas. Br. J. Cancer. 84 (11), 1497–1504 (2001).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Tashima, S., Shimada, S., Yamaguchi, K., Tsuruta, J. & Ogawa, M. Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am. J. Gastroenterol. 95 (1), 255–263 (2000).ArticleÂ
CASÂ
Google ScholarÂ
Takashi, M., Koshikawa, T., Kurobe, N. & Kato, K. Elevated concentrations of brain-type glycogen phosphorylase in renal cell carcinoma. Jpn J. Cancer Res. 80 (10), 975–980 (1989).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Shimada, S., Tashima, S., Yamaguchi, K., Matsuzaki, H. & Ogawa, M. Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase. J. Exp. Clin. Cancer Res. 18 (1), 111–118 (1999).CASÂ
Google ScholarÂ
Zhou, Y., Jin, Z. & Wang, C. Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p. Biomed. Pharmacother. 120, 109449 (2019).ArticleÂ
CASÂ
Google ScholarÂ
Murai, J. Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int. J. Clin. Oncol. 22 (4), 619–628 (2017).ArticleÂ
CASÂ
Google ScholarÂ
Nayak, A. P., Kapur, A., Barroilhet, L. & Patankar, M. S. Oxidative phosphorylation: a target for Novel therapeutic strategies against ovarian Cancer. Cancers (Basel) 10(9), 337 (2018).Huang, W. et al. Proteasome inhibitor YSY01A enhances cisplatin cytotoxicity in cisplatin-resistant human ovarian Cancer cells. J. Cancer. 7 (9), 1133–1141 (2016).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Bazzaro, M. et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 66 (7), 3754–3763 (2006).ArticleÂ
CASÂ
Google ScholarÂ
Klinck, R. et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res. 68 (3), 657–663 (2008).ArticleÂ
CASÂ
Google ScholarÂ
Pawlak, G. & Helfman, D. M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 11 (1), 41–47 (2001).ArticleÂ
CASÂ
Google ScholarÂ
Provenzano, P. P. & Keely, P. J. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and rho GTPase signaling. J. Cell. Sci. 124 (Pt 8), 1195–1205 (2011).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Ayollo, D. V., Zhitnyak, I. Y., Vasiliev, J. M. & Gloushankova, N. A. Rearrangements of the actin cytoskeleton and e-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One. 4 (11), e8027 (2009).ArticleÂ
ADSÂ
PubMed CentralÂ
Google ScholarÂ
Luo, X. et al. Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9. Biomolecules ; 13(12). (2023).Song, G. Q. et al. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma. Aging (Albany NY). 15 (22), 12907–12926 (2023).ArticleÂ
CASÂ
Google ScholarÂ
Olingy, C. E., Dinh, H. Q. & Hedrick, C. C. Monocyte heterogeneity and functions in cancer. J. Leukoc. Biol. 106 (2), 309–322 (2019).ArticleÂ
CASÂ
Google ScholarÂ
Almeida-Nunes, D. L., Mendes-Frias, A., Silvestre, R., Dinis-Oliveira, R. J. & Ricardo, S. Immune Tumor Microenvironment in Ovarian Cancer Ascites. Int J Mol Sci ; 23(18). (2022).Nowak, M. & Klink, M. The role of Tumor-Associated macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells 9(5), 1299 (2020).Addeo, A., Friedlaender, A., Banna, G. L. & Weiss, G. J. TMB or not TMB as a biomarker: that is the question. Crit. Rev. Oncol. Hematol. 163, 103374 (2021).ArticleÂ
Google ScholarÂ
Wu, H. X. et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann. Transl Med. 7 (22), 640 (2019).ArticleÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Marcus, L. et al. FDA approval Summary: Pembrolizumab for the treatment of Tumor Mutational Burden-High Solid tumors. Clin. Cancer Res. 27 (17), 4685–4689 (2021).ArticleÂ
ADSÂ
CASÂ
PubMed CentralÂ
Google ScholarÂ
Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 39 (2), 154–173 (2021).ArticleÂ
CASÂ
Google ScholarÂ